Houston Methodist announced today, in partnership with the U.S. Department of Health and Human Services (HHS), that it has expanded access to COVID-19 monoclonal antibody therapy (mAb) in the Greater Houston area. The promising treatment has been shown to keep high-risk COVID-19 patients out of the hospital and reduce the likelihood of progression to severe disease.
The State University of New York has awarded grants of up to $10,000 to three teams at Binghamton University to pursue research projects related to COVID-19.
As researchers try to develop therapies/vaccines to combat SARS-CoV-2, the coronavirus spike protein is a major focus since it can bind to cells. Now, researchers reporting in ACS Central Science have uncovered an active role for glycans in this process, suggesting targets for vaccines and therapies.
As the global response to the SARS-COV-2 virus that causes COVID-19 approaches 200 days, Baylor Scott & White Research Institute, the research and development arm of Baylor Scott & White Health, is accelerating its pace of bringing clinical trials online.
Baylor Scott & White Research Institute continues to mobilize staff and resources, including components needed to integrate critical patient-safety measures at every participating site within the Baylor Scott & White system for industry sponsored drug trials, investigator-initiated drug trials and research studies, and observational and data studies designed to help increase knowledge around case trends, viral epidemiology, and care best practices.
Memorial Sloan Kettering Cancer Center (MSK) announces its most recent awards and appointments for the institution’s physicians, scientists, nurses, and staff.
According to Rajesh R. Naik , “The current COVID19 crisis provides opportunities for the materials research community to provide solutions to overcome some of the challenges posed by the pandemic in areas such as decontamination, diagnostics and personal protective equipment…
Montefiore Health System and Albert Einstein College of Medicine have begun the next stage of the Adaptive COVID-19 Treatment Trial (ACTT), to evaluate treatment options for people hospitalized with severe COVID-19 infection. The new iteration of the trial, known as ACTT 2, is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
One of the many unanswered scientific questions about COVID-19 is whether it is seasonal like the flu – waning in warm summer months then resurging in the fall and winter. Now scientists at Lawrence Berkeley National Laboratory (Berkeley Lab) are launching a project to apply machine-learning methods to a plethora of health and environmental datasets, combined with high-resolution climate models and seasonal forecasts, to tease out the answer.
Chest X-rays performed on young and middle-aged adults with COVID-19 when they arrive at the emergency room can help doctors predict who is at higher risk of severe illness and intubation, Mount Sinai researchers report.
Government agencies and medical institutions have been hit hard recently by hackers attempting to steal coronavirus research. The US and other countries are battling to keep their coronavirus innovations secret (or protect their research in other ways) partly because they…
A new study from the Icahn School of Medicine at Mount Sinai suggests that blood clots, especially in the lungs, may play a role in severe cases of COVID-19.
Researchers from Intermountain Healthcare and University of Utah Health in Salt Lake City have launched two vital clinical trials to test the effectiveness and safety of two drugs – hydroxychloroquine (HCQ) and azithromycin – to treat patients with COVID-19.
Hsueh-Chia Chang, the Bayer Professor of Chemical and Biomolecular Engineering, said technology his lab developed for other uses could easily be extended to apply to testing for the coronavirus.